Tarsus Pharmaceuticals, Inc. TARS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$6.97M+72.3% | -$8.37M+63.8% | -$12.59M+46.3% | -$20.34M+38.9% | -$25.12M+29.7% | ||
| $197K-10.5% | $202K+5.2% | $200K0.0% | $200K+100% | $220K+29.4% | ||
| $11.97M+72.7% | $14.31M+93.4% | $12.24M+65.1% | $8.23M+10.1% | $6.93M+25.6% | ||
| $159K+14.4% | $156K+13.0% | $152K+17.8% | $146K+44.6% | $139K+21.9% | ||
| $30.29M+93.3% | $12.44M-29.3% | $14.29M— | —— | $15.67M+18.1% | ||
| $196K+133% | $536K— | $0-100% | $1.17M+68.8% | $84K-91.0% | ||
| -$9.25M-57.0% | $4.23M-6.0% | —— | —— | -$5.89M+19.2% | ||
| -$141K-12.8% | $381K— | $373K+1,592% | -$102K+78.9% | -$125K-17.9% | ||
| $13.24M+252% | -$8.19M-206% | -$7.98M-794% | $23.17M+3,121% | -$8.73M-719% | ||
| $240K0.0% | $241K+0.4% | $200K+100% | $200K+100% | $240K+140% | ||
| -$189K-144% | $336K+118% | —— | $179K— | $429K+12.0% | ||
| -$24.65M-19.4% | —— | —— | -$29.39M-104% | -$20.65M+45.4% | ||
| $5.82M+886% | $6.36M+8,731% | $1.91M+577% | $1M-3.7% | $590K+239% | ||
| $126.8M+1.0% | $35.58M-60.5% | $102.33M+385% | $129.7M+176% | $125.57M+20.1% | ||
| -$58.56M-67.6% | —— | -$4.74M— | -$51.7M-27.6% | -$34.94M+65.8% | ||
| $0-100% | —— | —— | —— | $135.13M+37.0% | ||
| $1.2M-99.1% | $2.31M-21.0% | $2.56M+301% | $1.95M-95.4% | $136.56M+25.6% | ||
| -$82.01M-201% | $70.92M+190% | $16.08M+429% | —— | $80.97M+359% | ||
| $1.97M-5.1% | $2.06M-5.3% | $2.12M-49.0% | $2.09M+347% | $2.07M+139% | ||
| $1.93M— | —— | —— | —— | $0— | ||
| $849K-35.4% | $925K-37.5% | $1.53M+34.1% | $1.71M+31.7% | $1.31M+353% | ||
| $159K+14.4% | $156K+13.0% | $152K+17.8% | $146K+44.6% | $139K+21.9% | ||
| $240K0.0% | $241K+0.4% | $200K+100% | $200K+100% | $240K+140% | ||
| $197K-10.5% | $202K+5.2% | $200K0.0% | $200K+100% | $220K+29.4% | ||
| -$9.25M-57.0% | $4.23M-6.0% | —— | —— | -$5.89M+19.2% | ||
| $7.71M+574% | —— | $23.84M+306% | $12.46M+75.8% | $1.14M-90.7% | ||
| $15.46M+52.1% | —— | —— | —— | $10.17M+7.6% | ||
| -$189K-144% | $336K+118% | —— | $179K— | $429K+12.0% | ||
| $13.24M+252% | -$8.19M-206% | -$7.98M-794% | $23.17M+3,121% | -$8.73M-719% | ||
| $77K-53.0% | $154K-11.0% | $205K+22.8% | $159K-2.5% | $164K+24.2% | ||
| $911K+2,236% | $32K-22.0% | $1.16M+2,000% | $305K+10,067% | $39K— | ||
| $0-100% | $0-100% | $0— | -$354K— | $354K+28.7% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $1.93M— | —— | —— | —— | $0— | ||
| -$30.47M-43.4% | —— | —— | -$30.39M-96.8% | -$21.24M+44.0% | ||
| -$30.47M-43.4% | —— | —— | -$30.39M-96.8% | -$21.24M+44.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Tarsus Pharmaceuticals, Inc. generate?
- Tarsus Pharmaceuticals, Inc. (TARS) generated -$96.9M in operating cash flow over the trailing twelve months.
- What is Tarsus Pharmaceuticals, Inc.'s free cash flow?
- After $15.1M of capital expenditures, Tarsus Pharmaceuticals, Inc.'s free cash flow was -$104.4M over the trailing twelve months, down 2.6% year over year.
- Where does Tarsus Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
